Promo !

Retatrutide/Cagrilitide 10 mg + 5 mg

Le prix initial était : $200.00.Le prix actuel est : $180.00.

Catégorie :

Retatrutide/Cagrilitide 10 mg + 5 mg research-grade lyophilized powder supplied in a sealed glass vial. This dual-compound formulation is studied in experimental models of metabolic regulation, appetite signaling and energy balance via incretin and amylin-related pathways.

Research Use Only: All products are intended exclusively for laboratory and scientific research. Not for human or veterinary use.

 

Purity
High-purity research grade

 

Form
Lyophilized powder

 

Content
Retatrutide 10 mg + Cagrilitide 5 mg (15 mg total) per vial

 

Total content
15 mg combined lyophilized peptide

 

Packaging
Sealed glass vial with sterile stopper

 

Storage
Store in a cool, dry place. Recommended storage below 18 °C.

 

Molecular formula
Not specified (peptide compounds)

 

Molecular weight
Not specified (peptide compounds)

 

IUPAC name
Retatrutide; Cagrilitide

 

CAS number
Retatrutide: 2381089-83-2
Cagrilitide: 1415456-99-3

Retatrutide/Cagrilitide

Research Overview

Retatrutide and cagrilitide are synthetic peptide analogues studied in advanced metabolic research. Retatrutide is investigated for its multi-receptor activity within incretin pathways, while cagrilitide is explored as a long-acting amylin analogue. In experimental settings, this combination is used to study appetite regulation, energy expenditure, glucose handling and metabolic signaling integration.

Primary Research Areas

  • Incretin & amylin signaling pathways: used to investigate combined modulation of GLP-1, GIP, glucagon and amylin-related receptor systems in metabolic research models.
  • Energy balance & appetite regulation: applied in experimental studies examining food intake behavior, satiety signaling and central–peripheral metabolic communication.
  • Glucose metabolism & insulin dynamics: explored in preclinical models assessing glycemic control, insulin sensitivity and pancreatic signaling responses.
  • Body-weight regulation models: studied in animal models of obesity and metabolic dysfunction to evaluate synergistic effects on adiposity and energy expenditure.
  • Neuroendocrine & metabolic integration: investigated for interactions between central appetite circuits, peripheral hormone signaling and adaptive metabolic responses.
Neither retatrutide nor cagrilintide is currently approved by regulatory bodies like the FDA, as both remain experimental drugs undergoing late-stage clinical trials. Combining them is an unapproved, off-label practice sometimes discussed in online spaces but lacking official medical safety guidelines. [1, 2, 3]
Drug Mechanisms
  • Retatrutide: A “triple-agonist” peptide that targets GLP-1, GIP, and glucagon receptors to lower blood sugar, suppress appetite, and boost calorie-burning energy expenditure. [1, 2]
  • Cagrilintide: A long-acting analog of the hormone amylin that targets amylin and calcitonin receptors to delay stomach emptying and increase feelings of fullness. [1]
Clinical Development Status
  • Retatrutide: Being evaluated by Eli Lilly in Phase 3 clinical trials (TRIUMPH program) for chronic weight management and obesity, with potential regulatory submissions anticipated. [1, 2]
  • Cagrilintide: Being studied primarily as a monotherapy or in combination regimens (such as with semaglutide in CagriSema) for enhanced metabolic and weight loss results. [1, 2]
Risks and Safety Concerns
  • Unapproved Stacking: Combining separate investigational peptides creates unknown pharmacokinetic interactions and unpredictable side effects.
  • Side Effects: Both classes independently cause gastrointestinal distress (nausea, vomiting, constipation) and potential increases in heart rate. [1, 2]
  • Gray Market Dangers: Sourcing these unapproved compounds outside formal clinical trials carries substantial purity, sterility, and dosing risks. [1, 2]
If you are looking for guidance on approved weight management treatments or want to know more about the clinical trial data for either drug, please let me know.

Can you use cagrilintide with retatrutide?

Combining cagrilintide and retatrutide lacks formal evaluation in published clinical trials, and neither medication holds regulatory approval as a standalone or combination treatment. Mechanistically, they target distinct, non-overlapping pathways—retatrutide acts as a triple GLP-1/GIP/glucagon receptor agonist, while cagrilintide is an amylin analog—but combining them significantly increases the risk of severe gastrointestinal distress and cumulative side effects.

Red Fox Peptides +3
Clinical and Practical Considerations
  • Regulatory Status: Both compounds remain investigational and are not approved by the US Food and Drug Administration (FDA) .
  • Mechanism: Retatrutide stimulates incretin and glucagon pathways, whereas cagrilintide targets amylin receptors to delay gastric emptying and increase satiety.
    Red Fox Peptides +1
  • Side Effects: Stacking these agents amplifies overlapping gastrointestinal risks, including intense nausea, vomiting, and delayed gastric emptying, alongside retatrutide’s unique effects on heart rate.
  • Lack of Data: No official dosing schedules, titration maps, or safety profiles exist for co-administering these two specific peptides.
Reconstitution

Recommended solvent — Bacteriostatic water

Bacteriostatic water 10ml

For diluting lyophilized peptide powders, use a sterile and suitable research solvent such as bacteriostatic water (BAC), which may help support handling stability and reduce contamination risk.

For convenient laboratory use, see Bacteriostatic water 10ml.

Why Limitless Biochem?

Limitless BioChem is a trusted supplier of research compounds. Our products meet strict quality standards and are compliant with EU requirements. We focus on the safe and reliable supply of peptides and pure compounds intended exclusively for research or collector purposes.

This product is not intended for human or veterinary use. It is for collection or research purposes only. It cannot be used as food, dietary supplement or medicine! The information provided in the text on this page is for educational purposes only and does not constitute medical or other advice.

Avis

Il n’y a pas encore d’avis.

Soyez le premier à laisser votre avis sur “Retatrutide/Cagrilitide 10 mg + 5 mg”

Votre adresse e-mail ne sera pas publiée. Les champs obligatoires sont indiqués avec *

Panier

Save to list